Natural Compounds as Non-Nucleoside Inhibitors of Zika Virus Polymerase through Integration of In Silico and In Vitro Approaches

• Autor(a) principal: Ramos, Paulo Ricardo Pimenta da Silva
• Data de Publicação: 2022
• Outros Autores: Mottin, Melina, Lima, Caroline Sprengel [UNESP], Assis, Letícia R. [UNESP], de Oliveira, Ketllyn Zagato, Mesquita, Nathalya Cristina de Moraes Roso, Cassani, Natasha Marques, Santos, Igor Andrade, Borba, Joyce Villa Verde Bastos, Fiaia Costa, Vinícius Alexandre, Neves, Bruno Junior, Guido, Rafael Victorio Carvalho, Oliva, Glaucius, Jardim, Ana Carolina Gomes, Regasini, Luis Octávio [UNESP], Andrade, Carolina Horta
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.3390/ph15121493; http://hdl.handle.net/11449/246535
• topic: antiviral; docking; drug discovery; flavonoid; non-nucleoside inhibitor; NS5 RdRp protein; pedalitin; polymerase; quercetin; Zika virus

Although the past epidemic of Zika virus (ZIKV) resulted in severe neurological consequences for infected infants and adults, there are still no approved drugs to treat ZIKV infection. In this study, we applied computational approaches to screen an in-house database of 77 natural and semi-synthetic compounds against ZIKV NS5 RNA-dependent RNA-polymerase (NS5 RdRp), an essential protein for viral RNA elongation during the replication process. For this purpose, we integrated computational approaches such as binding-site conservation, chemical space analysis and molecular docking. As a result, we prioritized nine virtual hits for experimental evaluation. Enzymatic assays confirmed that pedalitin and quercetin inhibited ZIKV NS5 RdRp with IC50 values of 4.1 and 0.5 µM, respectively. Moreover, pedalitin also displayed antiviral activity on ZIKV infection with an EC50 of 19.28 µM cell-based assays, with low toxicity in Vero cells (CC50 = 83.66 µM) and selectivity index of 4.34. These results demonstrate the potential of the natural compounds pedalitin and quercetin as candidates for structural optimization studies towards the discovery of new anti-ZIKV drug candidates.